Biocon shares rally nearly 6% after unit receives USFDA nod for cancer drug

April 11, 2025

Biocon’s shares surged following USFDA approval for Jobevne, a biosimilar to Avastin, used in treating various cancers. This marks Biocon’s seventh biosimilar approval in the U.S., strengthening its oncology portfolio. With bevacizumab sales reaching $2 billion in the U.S. in 2023, this approval signifies a major milestone for Biocon.

More To Explore

Ahead of Market: 10 things that will decide stock market action on Monday

Indian equities extended losses for a fifth straight session, pressured by elevated oil prices and persistent FII outflows. Despite intraday recovery, sentiment remains weak amid

July 26, 2026

IPO Buzz: Over a dozen firms, including Zepto set for debut next month

Next month is set to see a flurry of IPO activity as over a dozen companies plan to launch their share offerings. Collectively, these IPOs

July 26, 2026

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information.

The information on this website does not constitute investment advice or a recommendation or a solicitation to engage in any investment activity. This website and its content are not intended for residents of the UAE, US, Canada, Australia, UK, Russia, North Korea, China, Japan, Hong Kong, Singapore and Iran.

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003